Perspective Therapeutics Inc. (CATX) - Total Assets
Based on the latest financial reports, Perspective Therapeutics Inc. (CATX) holds total assets worth $410.77 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CATX cash flow metrics for how efficiently the company converts equity into cash flow.
Perspective Therapeutics Inc. - Total Assets Trend (1994–2025)
This chart illustrates how Perspective Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. See Perspective Therapeutics Inc. share price for real-time trading data and today's change.
Perspective Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Perspective Therapeutics Inc.'s total assets of $410.77 Million consist of 55.6% current assets and 44.4% non-current assets. Explore CATX working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.5% |
| Accounts Receivable | $6.00K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $40.00 Million | 15.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1994–2025)
This chart illustrates how Perspective Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Perspective Therapeutics Inc.'s current assets represent 55.6% of total assets in 2025, an increase from 29.3% in 1994.
- Cash Position: Cash and equivalents constituted 11.5% of total assets in 2025, down from 14.9% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is intangible assets at 15.0% of total assets.
Perspective Therapeutics Inc. Competitors by Total Assets
Key competitors of Perspective Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
|
Vieworks Co. Ltd
KQ:100120
|
Korea | ₩351.89 Billion |
|
T&L Co. Ltd
KQ:340570
|
Korea | ₩253.22 Billion |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
Perspective Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.75 | 17.02 | 9.21 |
| Quick Ratio | 8.75 | 17.02 | 8.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $243.87 Million | $203.06 Million | $10.95 Million |
Perspective Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Perspective Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.07 |
| Latest Market Cap to Assets Ratio | 1.66 |
| Asset Growth Rate (YoY) | -21.7% |
| Total Assets | $266.97 Million |
| Market Capitalization | $442.39 Million USD |
Valuation Analysis
Above Book Valuation: The market values Perspective Therapeutics Inc.'s assets above their book value (1.66x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Perspective Therapeutics Inc.'s assets decreased by 21.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Perspective Therapeutics Inc. (1994–2025)
The table below shows the annual total assets of Perspective Therapeutics Inc. from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $266.97 Million | -21.73% |
| 2024-12-31 | $341.10 Million | +248.45% |
| 2023-12-31 | $97.89 Million | +68.51% |
| 2023-06-30 | $58.09 Million | 0.00% |
| 2022-12-31 | $58.09 Million | -9.85% |
| 2022-06-30 | $64.44 Million | 0.00% |
| 2021-12-31 | $64.44 Million | -8.49% |
| 2021-06-30 | $70.42 Million | +353.92% |
| 2020-12-31 | $15.51 Million | +78.33% |
| 2020-06-30 | $8.70 Million | 0.00% |
| 2019-12-31 | $8.70 Million | -7.67% |
| 2019-06-30 | $9.42 Million | 0.00% |
| 2018-12-31 | $9.42 Million | +26.38% |
| 2018-06-30 | $7.46 Million | -39.24% |
| 2017-12-31 | $12.27 Million | 0.00% |
| 2017-06-30 | $12.27 Million | -32.22% |
| 2016-12-31 | $18.10 Million | 0.00% |
| 2016-06-30 | $18.10 Million | -21.31% |
| 2015-12-31 | $23.00 Million | 0.00% |
| 2015-06-30 | $23.00 Million | -13.36% |
| 2014-12-31 | $26.55 Million | 0.00% |
| 2014-06-30 | $26.55 Million | +276.30% |
| 2013-12-31 | $7.06 Million | 0.00% |
| 2013-06-30 | $7.06 Million | -6.00% |
| 2012-12-31 | $7.51 Million | 0.00% |
| 2012-06-30 | $7.51 Million | -4.86% |
| 2011-12-31 | $7.89 Million | 0.00% |
| 2011-06-30 | $7.89 Million | -0.68% |
| 2010-12-31 | $7.94 Million | 0.00% |
| 2010-06-30 | $7.94 Million | -32.35% |
| 2009-12-31 | $11.74 Million | 0.00% |
| 2009-06-30 | $11.74 Million | -34.08% |
| 2008-12-31 | $17.81 Million | 0.00% |
| 2008-06-30 | $17.81 Million | -31.69% |
| 2007-12-31 | $26.08 Million | 0.00% |
| 2007-06-30 | $26.08 Million | +361.04% |
| 2006-12-31 | $5.66 Million | 0.00% |
| 2006-06-30 | $5.66 Million | -82.64% |
| 2005-06-30 | $32.59 Million | 0.00% |
| 2004-12-31 | $32.59 Million | +3519014.47% |
| 2004-06-30 | $926.00 | 0.00% |
| 2003-12-31 | $926.00 | 0.00% |
| 2003-06-30 | $926.00 | 0.00% |
| 2002-12-31 | $926.00 | 0.00% |
| 2002-06-30 | $926.00 | -3.44% |
| 2001-12-31 | $959.00 | +0.42% |
| 2000-12-31 | $955.00 | -0.42% |
| 2000-06-30 | $959.00 | -99.92% |
| 1999-12-31 | $1.17 Million | +122847.23% |
| 1999-06-30 | $955.00 | -99.93% |
| 1998-12-31 | $1.31 Million | +11.74% |
| 1998-06-30 | $1.17 Million | -32.56% |
| 1997-12-31 | $1.74 Million | +32.70% |
| 1997-06-30 | $1.31 Million | -33.19% |
| 1996-12-31 | $1.96 Million | +12.80% |
| 1996-06-30 | $1.74 Million | -39.48% |
| 1995-12-31 | $2.88 Million | +46.49% |
| 1995-06-30 | $1.96 Million | -31.74% |
| 1994-12-31 | $2.88 Million | 0.00% |
| 1994-06-30 | $2.88 Million | -- |
About Perspective Therapeutics Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors t… Read more